Acute Leukemia explained: Types and treatment
Key Takeaways
Acute leukemia is a rapidly progressing cancer that originates in the bone marrow and disrupts normal blood cell production.
It requires early diagnosis and prompt treatment to improve survival outcomes.
There are two main types: Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML).
Genetic mutations, environmental exposures, prior cancer treatments, and inherited conditions may increase risk.
Symptoms often result from low blood counts and bone marrow failure.
Diagnosis involves blood tests, bone marrow examination, and advanced genetic analysis.
Treatment typically includes intensive chemotherapy, targeted therapy, immunotherapy, and sometimes stem cell transplantation.
Supportive care plays a crucial role in managing complications and improving quality of life.
Acute leukemia is an aggressive form of blood cancer that develops rapidly in the bone marrow. It occurs when immature blood cells, known as blasts, multiply uncontrollably and interfere with the production of normal blood cells.
Unlike chronic leukemia, which progresses slowly over years, acute leukemia advances quickly and often requires urgent medical intervention. Early detection and modern therapeutic strategies have significantly improved patient outcomes in recent decades.
This article explains the causes, types, symptoms, diagnostic methods, and treatment options for acute leukemia in a clear and comprehensive way.
What is Acute Leukemia?
Acute Leukemia is a malignant blood disorder that begins in the bone marrow, the soft tissue inside bones responsible for producing blood cells. Under normal conditions, the bone marrow produces three essential types of cells: red blood cells that carry oxygen throughout the body, white blood cells that help fight infections, and platelets that control bleeding and support blood clotting.
In acute leukemia, genetic mutations affect immature blood cells in the bone marrow and prevent them from developing into healthy, fully functional cells. Instead of maturing normally, these abnormal cells multiply rapidly and accumulate in the bone marrow and bloodstream.
As the number of leukemic cells, often called blasts, increases, they begin to crowd out healthy blood cells. This disruption in normal blood production can lead to several serious complications, including anemia due to a shortage of red blood cells, a higher risk of infections because of weakened immune defenses, and bleeding disorders caused by low platelet levels.
Because acute leukemia progresses quickly and can severely affect normal blood function, it is considered a medical emergency once diagnosed and usually requires immediate medical treatment.
Symptoms of Acute Leukemia
Symptoms occur mainly due to bone marrow failure and reduced production of normal blood cells. They often develop rapidly over weeks.
Symptoms related to Anemia
When red blood cell production decreases, patients may experience:
Persistent fatigue
Pale skin
Shortness of breath
Weakness
Dizziness
These symptoms result from reduced oxygen delivery to tissues.
Symptoms related to Low Platelets
Platelets prevent bleeding. When their levels drop, patients may develop:
Easy bruising
Frequent nosebleeds
Bleeding gums
Small red spots on the skin (petechiae)
Prolonged bleeding from minor injuries
Symptoms related to low white blood cells
A weakened immune system increases infection risk:
Recurrent infections
Persistent fever
Slow recovery from common illnesses
Severe or unusual infections
Additional symptoms
Other possible manifestations include:
Bone pain
Joint pain
Swollen lymph nodes
Enlargement of the spleen or liver
Unexplained weight loss
Because symptoms are nonspecific, medical evaluation is necessary for accurate diagnosis.
Types of Acute Leukemia
Acute leukemia is a rapidly progressing cancer that affects the blood and bone marrow. It is classified mainly according to the type of blood cell involved and the origin of the abnormal cells. The two primary types are Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML).
Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia originates from lymphoid precursor cells. These are immature cells that normally develop into lymphocytes, which are white blood cells responsible for immune defense against infections.
ALL develops when genetic mutations occur in these immature lymphocytes. These mutations cause the cells to multiply uncontrollably and fail to mature properly. As a result, abnormal leukemic cells accumulate in the bone marrow and blood and interfere with normal blood cell production.
Key characteristics
It is the most common leukemia in children.
It also occurs in adults, although less frequently than in pediatric patients.
It accounts for the majority of leukemia cases diagnosed in childhood.
It progresses rapidly and requires early diagnosis and intensive treatment.
How ALL affects the body
Because leukemic cells fill the bone marrow, they reduce the production of normal blood cells. This leads to several complications:
Anemia due to decreased red blood cell production, causing fatigue, weakness, and pale skin.
Thrombocytopenia due to low platelet levels, which leads to easy bruising, bleeding gums, and nosebleeds.
Reduced or dysfunctional white blood cells, increasing the risk of infections.
Leukemic cells may also spread to other parts of the body such as:
Lymph nodes
Liver and spleen
Central nervous system, including the brain and spinal cord
Testes in male patients
Subtypes of ALL
ALL is classified into subtypes based on the type of lymphoid cell involved and specific genetic features.
B-cell ALL (B-ALL)
The most common subtype of ALL.
Originates from immature B lymphocytes.
Represents the majority of ALL cases.
Prognosis depends on genetic abnormalities, age, and response to therapy.
T-cell ALL (T-ALL)
Develops from immature T lymphocytes.
More frequently seen in adolescents and young adults.
Often associated with a higher white blood cell count at diagnosis.
May present with a mediastinal mass affecting the thymus and surrounding structures.
Role of genetics in ALL
Genetic abnormalities play an important role in determining prognosis and treatment strategies. Genetic testing is used to classify risk groups and guide therapy.
Common genetic abnormalities include:
Chromosomal translocations
Gene rearrangements
Abnormal chromosome numbers such as hyperdiploidy or hypodiploidy
Mutations that affect cell signaling and growth pathways
Targeted therapies and risk-adapted treatment protocols are often based on these genetic findings.
Acute Myeloid Leukemia (AML)
Acute myeloid leukemia affects myeloid precursor cells. These cells normally develop into:
Red blood cells
Platelets
Granulocytes such as neutrophils, basophils, and eosinophils
Monocytes
In AML, genetic mutations disrupt normal cell development. The affected cells fail to mature and instead accumulate as abnormal blasts in the bone marrow and bloodstream. This accumulation suppresses the production of healthy blood cells.
AML is more common in adults and elderly individuals, but it can occur at any age, including children.
Key characteristics
More frequent in adults compared to children.
Has a higher incidence in older populations.
Progresses rapidly and requires immediate medical intervention.
Classified into multiple subtypes based on laboratory and genetic analysis.
Classification of AML subtypes
AML subtypes are defined by several factors:
Morphological features observed under a microscope.
Cytogenetic abnormalities detected through chromosome analysis.
Molecular mutations identified through genetic testing.
Common genetic mutations associated with AML include:
FLT3 mutations
NPM1 mutations
CEBPA mutations
TP53 mutations
These mutations influence treatment response, risk of relapse, and overall prognosis.
Clinical impact of AML
Because AML interferes with normal bone marrow function, patients may develop:
Severe anemia
Increased risk of infections due to low neutrophil counts
Bleeding and bruising from reduced platelet production
In advanced cases, AML cells can spread to organs such as the liver, spleen, lymph nodes, and sometimes the central nervous system.
Causes and risk factors
Acute leukemia results from genetic mutations in bone marrow stem cells. In most cases, the exact cause remains unknown. However, several risk factors have been identified.
Genetic predisposition
Some inherited conditions increase risk, including:
Down syndrome
Fanconi anemia
Germline mutations affecting DNA repair
These conditions significantly raise susceptibility to leukemia in some individuals.
Previous cancer treatments
Patients who received Chemotherapy, Radiation therapy for other cancers may develop therapy-related leukemia years later. Certain chemotherapy drugs and repeated exposure to ionizing radiation increase the risk of secondary leukemia.
Environmental and chemical exposure
Exposure to toxic substances may contribute to DNA damage, including:
Benzene (found in industrial settings and cigarette smoke)
Pesticides
Diesel exhaust
Long-term exposure to chemical solvents
Although occupational safety standards reduce risk, exposure remains a contributing factor in some cases.
Viral and immune-related factors
Some viruses, such as HTLV-1 and the Epstein-Barr virus, are associated with specific leukemia or lymphoma subtypes.
Patients with weakened immune systems or autoimmune diseases may also have a higher susceptibility.
Diagnosis of Acute Leukemia
Diagnosis of acute leukemia is based on a combination of laboratory investigations and specialized hematological examinations. These tests allow physicians to confirm the presence of abnormal cells, identify the leukemia subtype, and determine the most appropriate treatment approach.
Blood tests
The first step in the diagnostic process usually involves a complete blood count (CBC). This routine test often reveals abnormalities that raise suspicion of acute leukemia. Common findings include anemia caused by reduced red blood cell production, thrombocytopenia characterized by a low platelet count, and abnormal levels of white blood cells. In many cases, immature cells known as blasts can be detected circulating in the peripheral blood.
In addition to the CBC, a blood smear examination is performed. Under microscopic evaluation, specialists assess the morphology of blood cells and search for the presence of immature or atypical cells. Detecting blasts in the bloodstream strengthens the suspicion of acute leukemia and indicates the need for further investigation through bone marrow analysis.
Bone Marrow examination
A definitive diagnosis of acute leukemia is confirmed through bone marrow examination. This procedure involves bone marrow aspiration and, in some situations, a bone marrow biopsy. The sample is usually collected from the pelvic bone and analyzed in a specialized laboratory.
During this assessment, physicians measure the percentage of blast cells present in the marrow. They also evaluate cell morphology to identify abnormal structural features and examine the degree of cellular infiltration, meaning how extensively leukemic cells have replaced normal bone marrow tissue.
Diagnosis is typically confirmed when blast cells exceed a specific threshold defined by international medical guidelines, combined with clinical and laboratory evidence. This examination also plays a crucial role in determining the precise classification of leukemia.
Genetic and molecular testing
Advanced genetic and molecular testing is an essential part of modern leukemia diagnosis. These analyses help identify chromosomal abnormalities and gene mutations that influence disease progression, prognosis, and treatment decisions.
Cytogenetic analysis, also known as karyotyping, is performed to study the number and structure of chromosomes in leukemic cells. Fluorescence in situ hybridization testing is used to detect specific genetic rearrangements or chromosomal translocations with greater precision. Molecular mutation analysis is also conducted to identify mutations that may guide targeted therapy options.
These specialized tests provide detailed information about the biological characteristics of leukemia. They allow physicians to personalize treatment strategies according to the genetic profile of the disease and improve therapeutic planning.
Treatment of Acute Leukemia
Treatment requires a structured and intensive approach. The goal is to achieve complete remission and prevent relapse.
Chemotherapy
Chemotherapy remains the fundamental treatment for acute leukemia and represents the first therapeutic step in most newly diagnosed patients. It works by destroying rapidly dividing leukemic cells and reducing the overall disease burden inside the bone marrow and bloodstream. Treatment protocols are intensive and usually delivered in specialized hospital centers under strict medical supervision. Chemotherapy is generally divided into structured phases to maximize effectiveness and reduce the risk of relapse.
Induction phase
The induction phase is the first and most critical step in treatment. Its primary objective is to achieve complete remission by eliminating as many detectable leukemia cells as possible.
During this phase, patients receive intensive chemotherapy combinations designed to rapidly reduce the number of blasts in the bone marrow and restore normal blood cell production. Blood counts are closely monitored, and supportive care is often required to manage complications such as infections or anemia. Achieving remission after induction therapy does not mean the disease is cured, but it represents a major milestone and a positive response to treatment.
Consolidation phase
After remission is achieved, the consolidation phase begins. Even when leukemia cells are no longer detectable under standard laboratory tests, microscopic residual cells may still remain in the body.
The goal of consolidation therapy is to eliminate these residual leukemic cells and significantly reduce the risk of relapse. This phase may include additional cycles of chemotherapy and, in some cases, high-dose therapy depending on the patient’s risk classification. Reducing minimal residual disease during this stage is essential for improving long-term survival outcomes.
Maintenance phase (Primarily in ALL)
The maintenance phase is mainly used in the treatment of acute lymphoblastic leukemia (ALL). It consists of long-term administration of lower doses of chemotherapy over an extended period, sometimes lasting several months to years.
The objective of maintenance therapy is to keep the leukemia under control and prevent disease recurrence after remission has been achieved. Patients undergoing this phase require regular follow-up visits and laboratory monitoring to adjust medication doses and manage potential side effects.
Treatment is typically administered in specialized hospital settings or oncology units to ensure close supervision and prompt management of complications.
Targeted Therapy
Targeted therapy represents a major advancement in the treatment of acute leukemia. Unlike traditional chemotherapy, which affects both healthy and cancerous rapidly dividing cells, targeted therapy specifically attacks molecular abnormalities or genetic mutations that drive leukemia cell growth.
By focusing on defined genetic alterations, these medications improve treatment precision and reduce unnecessary damage to normal cells.
Examples of targeted therapies include:
FLT3 inhibitors used in certain subtypes of acute myeloid leukemia
Tyrosine kinase inhibitors used in Philadelphia chromosome-positive acute lymphoblastic leukemia
These treatments have significantly improved outcomes in patients whose leukemia carries specific genetic mutations. Genetic testing performed at diagnosis plays a crucial role in identifying candidates for targeted therapy. Targeted agents are often combined with chemotherapy or other treatments to enhance effectiveness and improve survival rates in selected patient groups.
Immunotherapy
Immunotherapy enhances the body’s immune system so it can better recognize and eliminate leukemia cells. This therapeutic approach has become increasingly important in cases where leukemia is resistant to standard treatments or has relapsed after initial therapy.
Immunotherapy options include:
Monoclonal antibodies that bind to specific proteins on leukemia cells and mark them for destruction
CAR-T cell therapy, an advanced treatment in which a patient’s own immune cells are genetically modified to attack leukemia cells
CAR-T cell therapy has shown remarkable success in certain high-risk or relapsed patients, particularly in acute lymphoblastic leukemia. It has produced high remission rates in cases where other therapies have failed.
Although immunotherapy offers promising results, it may be associated with specific immune-related side effects and therefore requires specialized monitoring in experienced treatment centers.
Stem Cell Transplantation
Hematopoietic stem cell transplantation is a powerful treatment option considered for patients with high-risk disease, relapse after initial therapy, or leukemia that does not respond adequately to standard treatments.
This procedure involves replacing diseased bone marrow with healthy stem cells obtained from:
A compatible donor
Or the patient themselves, depending on the clinical situation
Before transplantation, patients usually receive high-dose chemotherapy to eliminate remaining leukemia cells and suppress the diseased marrow.
Stem cell transplantation may offer a potential curative approach in selected patients. However, it is an intensive procedure associated with risks such as infection, graft-versus-host disease, and treatment-related complications. Therefore, careful patient selection and comprehensive medical evaluation are essential before proceeding.
Conclusion
Acute leukemia is an aggressive but treatable form of blood cancer. Early diagnosis, molecular classification, and personalized treatment strategies have transformed patient outcomes in recent years.
Modern approaches combining chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation offer improved survival and remission rates.
Ongoing monitoring and multidisciplinary care remain essential to achieve the best possible results for patients.